Skip to content

The Effect of Intrapartum Antibiotic Prophylaxis to Prevent Group B Streptococcal Early-onset Disease on Intestinal Microbiome and Immunity of Offspring

The Effect of Intrapartum Antibiotic Prophylaxis to Prevent Group B Streptococcal Early-onset Disease on Intestinal Microbiome and Immunity of Offspring

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200057783
Enrollment
Unknown
Registered
2022-03-17
Start date
2022-04-01
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonization of Group B Streptococcus

Interventions

Reproductive tract GBS colonization group of mothers during pregnancy:None
No reproductive tract GBS colonization group in mothers during pregnancy:None

Sponsors

Zhujiang Hospital, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 3 Years

Inclusion criteria

Inclusion criteria: 1. Infants: 37-41 weeks of age, born through vaginal delivery, 2500g<= birth weight < 4000g, 0-3 years of age; 2. The mother: birth ranging in age from 18 to 40 years old, the single pregnancy, pregnancy 35 - 41 weeks to complete the GBS screening; 3. The guardian agrees to participate in the study voluntarily.

Exclusion criteria

Exclusion criteria: 1. Infants and children with serious congenital abnormalities, infections or clinical diseases; 2. Antibiotics should be used in infants within 2 weeks, probiotics, prebiotics and biostime should be supplemented, or long-term drug treatment should be given for digestive, immune, blood and other diseases; 3. Infant mothers: childbirth after long-term drug treatment due to digestive, immune, blood and chronic diseases during pregnancy; Or infants who were breastfed within 12 hours of antibiotic use after delivery; 4. Any medical or non-medical condition that the investigator deems inappropriate to participate in.

Design outcomes

Primary

MeasureTime frame
Microbiology;Immunoassay;

Countries

China

Contacts

Public ContactWang Qian
wangqian@smu.edu+86 20 61643888

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026